Individuals from academia, the pharmaceutical industry, and the US Food and Drug Administration used a workshop format to discuss important methodological issues in the design of trials of pharmacological agents for improving negative symptoms in schizophrenia.
Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RSE. Methodological issues in negative symptom trials. Schizophrenia Bulletin, 2011; 37(2): 250-254. (PMCID: PMC3044631).